CAJ | 학술논문

目的观察替米沙坦对高血压并糖尿病患者血管紧张素转换酶2(ACE2) mRNA表达的影响.方法 62例高血压并糖尿病患者随机分为常规治疗组和替米沙坦组,测定各组用药前后外周血单核来源巨噬细胞ACE、ACE2 mRNA的表达.结果 (1)各组治疗4、12周后血压均降低,替米沙坦组降压效果强于常规治疗组(P＜0.05)；(2)治疗12周后替米沙坦组糖化血红蛋白下降较常规组明显,但差异无统计学意义(P＞0.05)；(3)治疗12周后替米沙坦组ACE2含量较常规治疗组明显增高[(23.9 ±8.2)U/L比(16.3±8.9) U/L,P＜0.05],ACE2 mRNA表达较常规治疗组明显增高(0.73 ±0.06比0.51 ±0.04,P＜0.01).结论替米沙坦对高血压并糖尿病患者降压、改善糖代谢的作用部分是通过增加ACE2活性及基因表达所致.
목적 관찰체미사탄대고혈압병당뇨병환자혈관긴장소전환매2(ACE2) mRNA표체적영향.방법 62례고혈압병당뇨병환자수궤분위상규치료조화체미사탄조,측정각조용약전후외주혈단핵래원거서세포ACE、ACE2 mRNA적표체.결과 (1)각조치료4、12주후혈압균강저,체미사탄조강압효과강우상규치료조(P＜0.05)；(2)치료12주후체미사탄조당화혈홍단백하강교상규조명현,단차이무통계학의의(P＞0.05)；(3)치료12주후체미사탄조ACE2함량교상규치료조명현증고[(23.9 ±8.2)U/L비(16.3±8.9) U/L,P＜0.05],ACE2 mRNA표체교상규치료조명현증고(0.73 ±0.06비0.51 ±0.04,P＜0.01).결론 체미사탄대고혈압병당뇨병환자강압、개선당대사적작용부분시통과증가ACE2활성급기인표체소치.
Objective To investigate the effects of telmisartan on the expression of angiotensin converting enzyme2 (ACE2) mRNA in monocyte-derived macrophages of hypertensive patients companied with diabetes.Methods 62 essential hypertensive patients companied with diabetes were randomly divided into two groups:regular treatment group,and telmisartan group.Then the content of ACE and ACE2 in serum was detected by ELISA,and the expression of ACE mRNA and ACE2 mRNA in monocyte-derived macrophages of patients was detected by RT-PCR before and after having been treated.Results (1) After having been treated for 4 weeks and 12 weeks,the blood pressure of the patients in two groups were decreased significantly,Comparing with regular group,telmisartan group seemed to have more obvious therapeutic effect (P ＜ 0.05) ; (2) After having been treated for 12 weeks,glycosylated hemoglobin diseased in both group,but there was no significant difference between the two group (P ＞ 0.05) ; (3) In telmisartan group,the content of ACE2 in serum was increased after having been treated for 12 weeks than that in regular treatment group,[(23.9 ± 8.2) U/L vs (16.3 ± 8.9) U/L,P ＜ 0.05] ; and the expression of ACE2 mRNA in monocyte-derived macrophages in telmisartan group was obviously increased after 12 weeks comparing with regular treatment group (0.73 ±0.06 vs 0.51 ±0.04,P ＜0.01).Conclusion The role of telmisartan in decreasing blood pressure and it's advantage to the metabolism of glucose are partly related with the up-regulation of ACE2 mRNA.